Gene Therapy Researchers Find a Viral Barcode to Cross the Blood-Brain Barrier
UNC School of Medicine scientists led by Aravind Asokan, PhD, reveal how certain gene-carrying AAV vectors can penetrate the brain more efficiently to treat brain and spinal cord conditions, while reducing liver payload.
Gene therapies promise to revolutionize the treatment of many diseases, including neurological diseases such as ALS. But the small viruses that deliver therapeutic genes can have adverse side effects at high doses. UNC School of Medicine researchers have now found a structure on these viruses that makes them better at crossing from the bloodstream into the brain – a key factor for administering gene therapies at lower doses for treating brain and spinal disorders.
“This structural ‘footprint’ we found seems to help these viruses get efficiently into the brain, which informs the design of potentially safer brain-targeted gene therapies,” said study senior author Aravind Asokan, PhD, associate professor of genetics.
The study examined adeno-associated viruses (AAVs), the most commonly used virus vectors for delivering gene therapies. The natural forms of these small viruses normally infect people without causing disease. For gene therapies, scientists remove most of the AAV genome, replace it with therapeutic genetic cargo, and inject trillions of copies into the patient.
Click here to read more.
2018 Advanced Endoscopic Skull Base and Pituitary Surgery
June 1-2, 2018; New York
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
June 2-5, 2018; Denver
Complex Endoscopic Endonasal Surgery of the Skull Base
June 7-9, 2018; Pittsburgh, PA
2018 Annual Meeting of the Michigan Association of Neurological Surgeons
June 8-10, 2018; Thompsonville, MI
CARS 2018 Computer Assisted Radiology and Surgery
June 20-23, 2018; Berlin, Germany
Be the first to reply using the above form.